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Objective. To investigate whether weight change during the early rheumatoid arthritis (RA) period is associated with subsequent mortality and to evaluate whether there is an RA-specific effect.
Methods. We identified patients with incident RA during the Nurses' Health Study (NHS; 1976 and created a comparison cohort by matching each RA patient with up to 10 non-RA comparators by age and calendar year of the RA diagnosis (index date). To capture weight change around the early RA period ("peri-RA/index"), we used weight measurements collected 2-4 years before and 2-4 years after the index date. We used Cox regression analysis to estimate hazard ratios (HRs) for mortality according to peri-RA/index weight change categories, separately in each cohort and in the combined cohorts, evaluating for an RA-specific effect.
Results. Among 121,701 women in the NHS, 902 patients with incident RA were identified and matched to 7,884 non-RA comparators. In the RA cohort, 371 deaths (41.1%) occurred during a mean follow-up of 17.0 years after the early RA period, and 2,303 deaths (29.2%) occurred in the comparison cohort during a mean followup of 18.4 years. Weight loss of >30 pounds during the peri-RA period had a hazard ratio (HR) for mortality of 2.78 (95% confidence interval [95% CI] 1.58-4.89) compared to stable weight; results in the comparison cohort were similar (HR 2.16, 95% CI 1.61-2.88). A weight gain of >30 pounds had no association with mortality in patients with RA (HR 1.45, 95% CI 0.69-3.07) or comparators (HR 1.19, 95% CI 0.89-1.59). For mortality, there was no statistically significant interaction between RA/ comparator status and weight change category (P = 0.68).
Conclusion. Severe weight loss during the early RA period was associated with an increased subsequent mortality risk for women with and those without RA. These results extend prior observations by including non-RA comparators and finding no protective association between weight gain and mortality, providing evidence against an RA-specific obesity paradox for mortality.
The increased mortality risk for patients with rheumatoid arthritis (RA) compared to the general population may be attributable to altered immunity, medication side effects, systemic effects of inflammation, worsened physical function, accumulation of multimorbidities, and excessive unhealthy behaviors such as smoking (1) (2) (3) (4) (5) . The contribution of metabolic and inflammatory factors (such as obesity) to RA etiology and outcomes has received increased attention recently (6, 7) . Several studies have investigated the effect of body mass index (BMI) on mortality in patients with RA. In RA cohorts, obesity has been associated with 34-67% decreased mortality compared to that in patients with a normal BMI (8) (9) (10) (11) . Follow-up studies suggested that this "obesity paradox" for mortality in RA may be explained by pathologic unintentional weight loss in the few years preceding death rather than a biologic protective effect of obesity. According to this explanation, patients with longstanding RA who reach normal weight or a BMI category of underweight have higher observed mortality and are relatively less healthy than RA patients who maintain obesity or a BMI category of overweight (11, 12) .
In patients with other chronic diseases and in the general population, similar findings of a paradoxical protective effect of overweight or obesity, as well as increased mortality risk with unintentional weight loss, have been reported (13) (14) (15) (16) . Studies evaluating obesity, weight change, and mortality in RA have typically had a long duration and a relatively short follow-up period prior to death. Therefore, previously observed associations may not have been specifically related to RA, but rather may have been detecting a general phenomenon related to multimorbidities, aging, or frailty (13, 17) .
We hypothesized that the early RA period is the window of time most likely to specifically contribute to weight change in RA patients with active symptoms due to systemic inflammation prior to treatment and changes in physical activity and diet with active symptoms (18, 19) . Therefore, to investigate the specific effect of weight change on mortality in RA, weight measurements are needed before the RA diagnosis and at the end of the early RA period to effectively capture weight changes that might occur during the entire early RA period. Furthermore, a non-RA population is required to establish that the observed effects are specifically related to RA and not to multimorbidities, aging, or frailty. Because weight loss often immediately precedes death, a lengthy period between weight change and death assessment enhances the ability to associate weight loss with RA.
Within the Nurses' Health Study (NHS), we investigated the effect of weight change during the early RA period on subsequent mortality and included a non-RA comparison cohort to determine whether there was an RA-specific effect. We hypothesized that severe weight loss and severe weight gain during the early RA period would be associated with an increased risk of mortality compared to stable weight, but that the effects would be similar in patients with RA and individuals without RA.
PATIENTS AND METHODS
Study population. In 1976, the NHS enrolled 121,701 female registered nurses in the US (ages 30-55 years). Women in the NHS completed questionnaires at baseline and then every 2 years, providing data on anthropometrics, behaviors, sociodemographics, diet, medications, and diseases. The response rate during follow-up in the NHS has been high, with >90% of subjects returning questionnaires each cycle (1) . All aspects of this study were approved by the Partners HealthCare Institutional Review Board.
Incident RA cohort. We excluded participants who had prevalent RA or other connective tissue disease (CTD) prior to the NHS baseline in 1976. Women who self-reported a diagnosis of RA or other CTD after the initial questionnaire were mailed a screening questionnaire (20) . For those with positive screening results, medical records were obtained and reviewed by 2 rheumatologists to confirm that the diagnosis of RA met the 1987 American College of Rheumatology classification criteria (21) . Details regarding RA characteristics at diagnosis, including date of diagnosis, serologic status, radiographic changes/erosions, and nodules, were obtained from review of the medical records. Seropositivity was defined as positivity for rheumatoid factor or cyclic citrullinated peptide (CCP) antibodies based on tests performed during routine medical care. Because women in whom RA was diagnosed prior to the clinical use of CCP antibody testing would not have had this test during clinical care, CCP antibody status was generally available only in women diagnosed with RA later during follow-up. We analyzed only RA patients who had weight measurements available for 2 questionnaire cycles before as well as 2 cycles after the date of the RA diagnosis ( Figure 1) .
Matched non-RA comparison cohort. To evaluate for an RA-specific effect of weight change on mortality, we created a comparison cohort of women without RA within the NHS. To control for age and temporal trends, we matched each RA patient with up to 10 non-RA comparators, based on age and calendar year. We defined the index date for matching as the date of the RA diagnosis, as previously described (5) . Participants in the NHS were eligible to be a comparator if they had never reported RA or any other CTD prior to or on the index date and had weight measurements obtained at 2 follow-up cycles before as well as 2 cycles after the index date. Because the women were matched based on the same age in years and same calendar year, exactly 10 comparators with complete exposure data may not have been available for every woman with incident RA.
Weight change in the early RA/index period. In all participants, weights (in pounds) were prospectively self-reported. Measurements obtained by self-report have been validated as being highly accurate compared to standardized measurements (r = 0.98) (22) . We investigated weight change during the early RA period, because this is the window of time during which weight change is most likely to be related to RA-specific processes ( Figure 1) .
We chose the initial weight (weight 1), reported 2 cycles (minimum of 2 years and maximum of 4 years) prior to the date of the RA diagnosis, because the weight measurement immediately preceding the RA diagnosis might have been affected by RA symptoms prior to a definitive clinical diagnosis. We chose the subsequent weight (weight 2), reported 2 cycles after the date of the RA diagnosis (minimum of 2 years and maximum of 4 years), to capture the early RA period, which is often defined as the first 2 years after diagnosis (23) (24) (25) . Therefore, we captured weight change in the "peri-RA" period, which encompassed the entire early RA period. For comparators, we used a parallel strategy to identify weights before and after the index date to define analogous "early index" and "peri-index" periods, even though these comparators had not been diagnosed with any disease at the index date. In this study, the entire peri-RA/ index period typically encompassed 6 years ( Figure 1) .
We created categories of weight change based on the absolute weight gain or loss, by comparing the initial and subsequent weights (Dweight = weight 2 À weight 1). We defined stable weight as |Dweight| ≤10 pounds, mild loss as Dweight <À10 to À20 pounds, moderate loss as Dweight <À20 to À30 pounds, severe loss as Dweight <À30 pounds, mild gain as Dweight >10 to 20 pounds, moderate gain as Dweight >20 to 30 pounds, and severe gain as Dweight >30 pounds.
Identification of deaths. As previously described in detail, deaths were identified by systematic searches of the National Death Index and state vital records (26) . This search was supplemented using family and postal authority reports. Use of these methods ascertained >98% of deaths in the NHS (27) . Women who died during the peri-RA or peri-index periods were not included in the analysis, since weight change could not be calculated. Complete death data were available until May 31, 2016, which was the end of the analysis.
Covariates. We considered covariates as confounders based on their association with both RA risk and mortality, as shown in previous studies. All covariates except RA disease characteristics were assessed at the same questionnaire cycle at which weight 1 was obtained. BMI was categorized as underweight, normal, overweight, or obese (28) . Age (in years) was used as a continuous variable. Annual household income was based on the home address and US Census Bureau tract-level data as a proxy for socioeconomic status (<$40,000 or ≥$40,000). Physical activity was first measured starting in 1980, using a validated survey, and was converted into continuous weekly hours of moderate or vigorous activity (29) . Dietary factors were assessed using semiquantitative food frequency questionnaires in 1980, 1984, 1986 , and every 4 years until 2014 (30) . Participants were classified into tertiles of the Alternate Healthy Eating Index to rank dietary quality, using previously described methods (31) . For the assessment of multimorbidities at baseline, we used the validated Multimorbidity Weighted Index (MWI) derived using the NHS and related cohorts, composed of 74 distinct self-reported prevalent and serious conditions (such as cancer, diabetes, and cardiovascular disease), with each condition weighted by the effect on physical health-related quality of life (32) . As in previous work, we excluded conditions affecting only men, premenopausal conditions not assessed in the NHS, and RA or other CTD (for a total of 64 conditions in this analysis) (5). In analyses of RA patients only, we further considered RA severity factors at diagnosis, including seropositivity as well as radiographic changes/erosions and nodules, that were collected from medical records at the time of the RA diagnosis. Data on RA-specific medications were unavailable, but participants had not yet been diagnosed with RA at baseline, when the initial weight measurement was reported.
Statistical analysis. We reported descriptive statistics at baseline (time of weight 1) according to the 7 categories of weight change (stable, mild loss, moderate loss, severe loss, mild gain, moderate gain, and severe gain) during the peri-RA/index period, separately for the RA and comparison cohorts. We reported the proportion of women in each weight change category according to cohort.
We investigated the effect of weight change during the peri-RA/index period on subsequent mortality. We initially performed analyses separately in each cohort. Person-years accrued from the end of the early RA/index period (starting after completion of the questionnaire that measured weight 2) until the end of follow-up, date of death, or date of censoring, whichever came first. Loss to follow-up and self-reported RA or CTD (for comparators) were censoring events. We used Cox regression analysis to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the association of weight change during the peri-RA/index period and subsequent mortality, with adjustment for age and questionnaire period. The next multivariable model adjusted for baseline BMI category. The final We used Kaplan-Meier curves to display death-free survival according to each of the 7 weight change categories after the end of the early RA/index period, defined as the questionnaire in which weight 2 was reported. We constructed separate plots for the RA and comparator cohorts. We tested for a difference between the curves using a log rank test.
To examine whether weight change during the peri-RA/ index period had a differential effect in women with RA compared to matched comparators, we combined both cohorts into a single analysis using an indicator variable. We tested for a multiplicative interaction for mortality between RA/comparator status and weight change, using an interaction term between these variables, and reported the P value.
We tested for the proportional hazards assumption by comparing nested models with and those without interaction terms with follow-up time using likelihood ratio tests. The proportional hazards assumption was met in all analyses. In all analyses, 2-sided P values less than 0.05 were considered significant. Analyses were performed using SAS version 9.4.
RESULTS
Among 121,701 women in the NHS, we identified 902 patients with incident RA and 7,884 matched non-RA * Weight data were obtained every 2 years during follow-up. The peri-rheumatoid arthritis (peri-RA) period was defined as up to 4 years before and 4 years after the RA diagnosis. The peri-index period was defined as up to 4 years before and 4 years after the index date for matched comparators. Each RA patient was matched with up to 10 comparators without RA or other connective tissue disease, for age and calendar year at the index date. 95% CI = 95% confidence interval. † Per 100,000 person-years. ‡ Adjusted for age in years (continuous) and calendar year. § Additionally adjusted for pre-RA/index date body mass index (BMI) (<18.5, 18.5-24.9, 25-29.9, 30-34.9, ≥35 kg/m 2 ). ¶ Additionally adjusted for cigarette smoking (never, past, current), physical activity (hours of moderate or vigorous exercise per week [continuous]), US Census Bureau tract-level household income (<$40,000 or ≥$40,000/year), the Alternative Healthy Index dietary score (tertiles), and the Multimorbidity Weighted Index (continuous). # Additionally adjusted for RA serologic status (seropositive, seronegative), rheumatoid nodules, and radiographic changes/erosions according to medical record review at the time of RA diagnosis. This model was not applicable to the comparison cohort.
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SPARKS ET AL comparators for whom weights measurements were available during the peri-RA/index period. The characteristics of both cohorts at the beginning of the peri-RA/index period are shown in Table 1 , stratified by weight change. In both cohorts, subjects with severe weight loss (>30 pounds) were older, exercised less frequently, had worse dietary quality, were more likely to be obese, were more likely to have ever smoked, and had a higher MWI than those with stable weight. Those with severe weight gain (>30 pounds) were younger than those with stable weight but exercised less, had a less healthy diet, were more likely to be obese, were more likely to ever have smoked, and had a higher MWI. In the RA cohort, patients with severe weight gain were less likely to be seropositive, have rheumatoid nodules, or have radiographic changes/erosions compared with those in the other weight change categories. Weight change during the peri-RA/index period. Table 2 shows the proportion of women in the RA and comparison cohorts in each category of weight change during the peri-RA/index period. Stable weight was most common in both cohorts (64.3% in the RA cohort and 69.1% in the comparison cohort). The percentage of women who lost weight was higher in the RA cohort (15.8% [3.0% with severe weight loss]) than in the comparison cohort (10.6% [1.6% with severe weight loss]). A similar proportion of women in the RA and comparator cohorts gained weight during the peri-RA/index period (for any gain, 19.9% and 20.5%, respectively; for severe gain, 2.4% and 2.3%, respectively).
Mortality rates after the early RA or matched index period. In the RA cohort, 371 deaths (41.1%) occurred during 16,006 person-years of follow-up after the early RA period (mean AE SD follow-up per woman 17.0 AE 8.8 years) ( Table 3 ). In the comparison cohort, 2,303 deaths (29.2%) occurred during 150,075 person-years of follow-up after the early index period (mean AE SD followup per woman 18.4 AE 9.4 years). The RA cohort had a higher absolute mortality rate (1,770-6,909 deaths/100,000 person-years) across all weight change categories compared with the comparison cohort (1,293-3,717 deaths/ 100,000 person-years).
Mortality in the RA cohort according to weight change during the peri-RA period. In the age-adjusted model, severe weight loss during the peri-RA period had an HR for subsequent mortality of 3.51 (95% CI 2.12-5.80) compared to stable weight. There was no statistically significant association between moderate weight loss or any level of weight gain during the peri-RA period (compared to stable weight) and mortality. However, mild weight loss during the peri-RA period had an HR for mortality of 1.72 (95% CI 1.22-2.42) compared to stable weight. These associations persisted after adjustment for baseline BMI, although the HR for mortality in women with severe weight loss was attenuated (HR 3.10, 95% CI 1.80-5.33). In the multivariable model with adjustment for baseline BMI, smoking, physical activity, diet quality, income, and multimorbidities, severe weight loss (HR 2.78, 95% CI 1.58-4.89) and mild loss (HR 1.78 , 95% CI 1.25-2.54) remained statistically significantly associated with increased subsequent mortality compared to stable weight. These associations were similar after further adjustment for the RA severity factors of serologic status, rheumatoid nodules, and erosions (for severe loss, HR 2.71 [95% CI 1.54-4.77] compared to stable weight). Figure 2A shows the Kaplan-Meier curves for survival after the end of the early RA period. The survival curves according to weight change categories were statistically significantly different (P < 0.0001). Survival was worst in patients with severe weight loss, followed by those with moderate weight loss and those with mild loss. The curves for stable weight and all weight gain categories were relatively similar. Among RA patients with severe weight loss, median survival was 8.0 years (interquartile range [IQR] 4.8-12.0). Among women with stable weight, median survival was 16.2 years (IQR 10.8-24.0) after the end of the early RA period.
Mortality in the comparison cohort according to weight change during the peri-index period. In the ageand BMI-adjusted analysis performed only in matched comparators, there were statistically significant associations of both weight loss and weight gain during the periindex period with subsequent mortality compared to stable weight (for severe loss, HR 2.42, 95% CI 1.81-3.22; for severe gain, HR 1.36, 95% CI 1.01-1.81). However, after further adjustment for smoking, physical activity, diet quality, income, and multimorbidities, only severe and moderate weight loss remained significantly associated with mortality. Severe weight loss during the peri-RA period had an HR for subsequent mortality of 2.16 (95% CI 1.61-2.88) in the multivariable model. Figure 2B shows the Kaplan-Meier curves for death-free survival after the end of the early index period in the comparison cohort. The survival curves according to weight change categories were statistically significantly different in this cohort (P < 0.0001). Similar to the Kaplan-Meier curves for survival in the RA cohort, the curves for survival in comparators in the stable weight and weight gain categories overlapped, while the weight loss categories showed a graded effect across categories of weight loss. The median survival for comparators with severe weight loss was 8.8 years (IQR 4.4-14.0). Women with stable weight had a median survival of 17.9 years (IQR 11.3-26.0) after the end of the early index period. Survival was longer in comparators than in women with RA in all analogous weight change categories.
Combined analysis of women with RA and matched comparators. Figure 3 shows the multivariable HRs for mortality in the combined analysis of RA patients and matched comparators (total of 8,786 women), with stable-weight comparators as the reference group. In this analysis, the 95% CIs were wide at the extreme weight change categories due to a small sample size, particularly in the RA cohort. Women with RA had a higher HR for mortality than did comparators in every weight change category. The highest HR for mortality in both RA 24 SPARKS ET AL patients and comparators was in the severe weight loss category. Women with RA who had severe weight loss during the peri-RA period had an HR for mortality of 2.92 (95% CI 1.83-4.66) compared to comparators with stable weight. Comparators with severe weight loss had an HR for mortality of 2.21 (95% CI 1.66-2.95) compared to comparators with stable weight. For mortality, there was no statistically significant interaction between RA/comparator status and weight change category (P = 0.68).
DISCUSSION
During 40 years of prospective follow-up, we observed that severe weight loss (defined as >30 pounds) around the time of the RA diagnosis, and a similar matched period among women without RA, was associated with increased mortality compared to stable weight. We studied weight change during the period around the time of the RA diagnosis, because weight change during this period is more likely to be related to intrinsic disease processes rather than general aging processes. Although the absolute risk of death for women with RA was higher than that for women without RA, there was a similar trend between the relative risk of mortality and weight change in both groups. Therefore, studies in which an association of BMI categories and weight loss with mortality risk in RA patients was reported may have been detecting general population effects rather than RA-specific effects.
Previous studies have established that mortality is increased in patients with RA compared to the general population (1) (2) (3) (4) . Recent investigations have focused on either RA-specific or potentially modifiable factors contributing to this mortality gap (5, (33) (34) (35) (36) . For example, smoking has been associated with worsened RA severity factors such as disease activity and erosions, which may in turn contribute to excess mortality. Our group recently reported that smoking contributes more to mortality risk in patients with RA than in matched non-RA comparators (5) . Because patients with RA have excess cardiovascular disease compared to the general population, cardiometabolic risk factors such as obesity may be related to outcomes including mortality (37) . In contrast to the generally adverse effects of obesity on many health outcomes, obesity has been paradoxically associated with a decreased risk of bone erosions in RA compared to a normal BMI (7) . This finding led to other investigations in which obesity was shown to be associated with the expected findings of worsened disease activity and functional status (7, 38, 39) . These discrepant results prompted further investigations of downstream events, including total and cause-specific mortality in RA (8, 9, 11, 12) .
These prior studies investigating the association of weight change and BMI categories with mortality were typically performed in RA-only cohorts of longstanding disease duration with relatively limited follow-up for death. Therefore, it was unclear whether the associations reported were related specifically to RA or were describing typical patterns that might emerge in any population of individuals who were frail and advanced in age. Patients with a normal BMI measured near the end of life may have reached this state due to pathologic weight loss and have higher-thanexpected mortality compared to patients in whom the BMI category of obesity or overweight was maintained. Therefore, near the end of life, individuals with a "normal" BMI may be relatively less healthy than those who are overweight or obese and remain that way by not losing weight (17) . This hypothesis is further supported by increased mortality in patients with a BMI in the underweight category, because elderly patients often unintentionally become underweight due to pathologic states rather than healthy, intentional weight loss through diet and physical activity (13) . Therefore, studying weight change has been considered a method to correct the "obesity paradox" of lowerthan-expected mortality in obese persons, particularly near the end of life (11) .
Two previous studies in RA cohorts used weight loss as a method to correct the obesity paradox for mortality in RA (11, 12) . Baker and colleagues showed that a BMI loss of ≥1 kg/m 2 was associated with a 2-fold increased risk of death compared to stable weight (11) . Patients who reached a BMI category of underweight after previously being obese had the highest risk of death (11) . A follow-up study investigated cause-specific mortality and showed that the highest weight loss rate and weight loss percentage were associated with a higher risk of cardiovascular-and cancer-related mortality, while a BMI category of underweight was associated with an increased risk of respiratory disease-related mortality (12) . Both studies were performed using data from the Veterans Affairs RA Registry and therefore were composed of mostly older men (mean age 63.5 years and 63.4 years, respectively), many with established RA (median duration 7.4 years and 8.2 years, respectively), and had a relatively limited follow-up for mortality (median duration 5.5 years and 3.2 years, respectively) (11, 12) .
Our study differs from these prior studies in several important ways. First, we included matched comparators who had identical measures assessed as the patients with RA. Second, because we identified incident RA during follow-up in the NHS, we could investigate weight change during the early RA period and create a similar time period for comparators. Therefore, we captured weight change near the time of RA diagnosis, when disease-specific processes were most likely to have contributed to weight change. Because pathologic weight loss often precedes death, we designed our study around RA diagnosis rather than observing weight changes near the end of life, which may be related to underlying pathologic processes leading to death rather than RA-specific processes (13) . Third, we investigated weight gain in addition to weight loss. Although pathologic weight loss is well known to portend a high risk of death in the general population as well as RA patients, weight gain is less studied, particularly in RA. Weight gain may have had a unique relationship with mortality in RA, because dietary changes, medication side effects, and physical activity changes might result in weight gain during the early RA period (40) . Because prior studies investigating weight loss included both weight stability and weight gain in the reference group, the relationship between weight loss, weight stability, and weight gain was previously unclear (11, 12) . Last, our study had a lengthy follow-up that commenced after the end of the early RA period.
We observed that severe weight loss (>30 pounds) increased mortality similarly in the RA and comparison cohorts. In both cohorts, this association was attenuated, but not completely explained, by adjustment for baseline BMI, smoking, physical activity, dietary quality, income, and multimorbidities. In the RA cohort, adjustment for RA severity factors at diagnosis, including serologic status, nodules, and radiographic change/erosions, did not explain the increased risk. As expected for a chronic disease, more RA patients than comparators had a weight loss of ≥10 pounds (15.8% versus 10.6%). Some of these patients with weight loss may have had rheumatoid cachexia, which has previously been associated with worse RA outcomes and increased mortality (41) . However, because mortality was similar in comparators with severe weight loss, rheumatoid cachexia does not fully explain the increased mortality in the RA patients with severe weight loss.
Although the obesity paradox for mortality may support the notion that weight gain could be protective against mortality, we hypothesized that individuals with severe weight gain would have increased mortality, which perhaps would be more evident among patients with RA because factors such as glucocorticoid use and decreased physical activity would presumably differentially affect those with RA. However, we observed that the proportion of subjects who experienced weight gain 26 SPARKS ET AL was similar in the RA and comparator cohorts (19.9% and 20.5%, respectively). Furthermore, we observed no statistical association between weight gain and mortality compared to stable weight in the early RA period. Although the point estimate (HR 1.45) for severe weight gain may suggest a modestly increased mortality risk in the RA cohort, the confidence interval was wide and was not statistically significant. It is possible that the current study was underpowered to detect a true effect of weight gain on mortality risk in RA, but it is unlikely that weight gain in the early RA period confers a protective effect against mortality. In the comparator cohort, there was a statistically significant association between weight gain and mortality that demonstrated a dose effect in the age-and BMI-adjusted analysis. However, this effect was no longer detectable after adjustment for confounders, despite adequate power. Overall, these results do not suggest that weight gain is strongly associated with subsequent risk of mortality independent of known mortality risk factors.
The current study has limitations that should be considered. The NHS is composed only of women, most of whom were white and were employed at baseline in 1976. It is unclear how generalizable these results might be to other contemporary populations. Overall, our results showing an association between severe weight loss and increased mortality are similar to the results of 2 prior studies investigating weight loss and mortality that were performed among mostly men with RA (11, 12) . We constructed the weight change period around the RA diagnosis as a time point that is relevant to all patients diagnosed with RA and chose the baseline period prior to RA diagnosis to protect against reverse causation with RA symptoms affecting the initial weight in patients with RA. It is still possible that early symptoms may have affected weight at the initial assessment among those in whom RA developed later.
Although we had detailed data available on covariates for adjustment, residual confounding by factors, such as the severity of multimorbidities rather than just their presence, may have affected the weight loss association. We did not have data available about RA characteristics after diagnosis, such as medication use, disease activity, or bone erosions/deformities. When adjusting for the RA severity factors that were available at diagnosis, we observed similar results. Because these RA characteristics are not relevant to comparators without RA, we would have been unable to investigate the effect of these factors in the combined analysis of RA patients and matched comparators. While BMI and weight have been widely used in epidemiologic analyses, patients with RA may have body compositions different from those of non-RA comparators that we were unable to analyze (42) . Because the reason for weight change was unavailable, we cannot determine whether women were intending to lose weight through diet and exercise. We suspect that severe weight loss may have been attributable to pathologic processes in most women. Therefore, these results should not be interpreted as discouraging healthy weight loss through diet and exercise.
In conclusion, we observed that severe weight loss during the early RA period was associated with an increased subsequent mortality risk for both RA patients and matched comparators. Compared to stable weight during the early RA period, weight gain was not associated with subsequent mortality risk for either RA patients or matched comparators. These results emphasize the need to consider a non-RA population when investigating the relationship between an exposure and an outcome that are not specifically related to the disease population of interest. These results extend prior reports on the effect of weight loss on mortality in RA and provide evidence that the findings were related to aging effects in the general population rather than specifically to RA. Although weight control during the early RA period may be important in disease processes such as bone erosions or disease activity, the relationship between weight change and mortality during the early RA period is likely similar to that observed in the general population.
